118 related articles for article (PubMed ID: 18285666)
1. Interlaboratory comparison of quantitative RT-PCR based detection for minimal residual disease in leukemias: a standardization approach in Japan.
Yamada MF; Fujiwara T; Ishikawa I; Kohata K; Katoh C; Miyamura K; Harigae H
Tohoku J Exp Med; 2008 Feb; 214(2):97-104. PubMed ID: 18285666
[TBL] [Abstract][Full Text] [Related]
2. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
Gabert J; Beillard E; van der Velden VH; Bi W; Grimwade D; Pallisgaard N; Barbany G; Cazzaniga G; Cayuela JM; Cavé H; Pane F; Aerts JL; De Micheli D; Thirion X; Pradel V; González M; Viehmann S; Malec M; Saglio G; van Dongen JJ
Leukemia; 2003 Dec; 17(12):2318-57. PubMed ID: 14562125
[TBL] [Abstract][Full Text] [Related]
3. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.
van Dongen JJ; Macintyre EA; Gabert JA; Delabesse E; Rossi V; Saglio G; Gottardi E; Rambaldi A; Dotti G; Griesinger F; Parreira A; Gameiro P; Diáz MG; Malec M; Langerak AW; San Miguel JF; Biondi A
Leukemia; 1999 Dec; 13(12):1901-28. PubMed ID: 10602411
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.
Beillard E; Pallisgaard N; van der Velden VH; Bi W; Dee R; van der Schoot E; Delabesse E; Macintyre E; Gottardi E; Saglio G; Watzinger F; Lion T; van Dongen JJ; Hokland P; Gabert J
Leukemia; 2003 Dec; 17(12):2474-86. PubMed ID: 14562124
[TBL] [Abstract][Full Text] [Related]
5. Assessment of a new RNA stabilizing reagent (Tempus Blood RNA) for minimal residual disease in onco-hematology using the EAC protocol.
Prezeau N; Silvy M; Gabert J; Picard C
Leuk Res; 2006 May; 30(5):569-74. PubMed ID: 16209886
[TBL] [Abstract][Full Text] [Related]
6. Quantitative detection of AML1-ETO rearrangement by real-time RT-PCR using fluorescently labeled probes.
Barragán E; Bolufer P; Moreno I; Martín G; Nomdedeu J; Brunet S; Fernández P; Rivas C; Sanz MA
Leuk Lymphoma; 2001 Aug; 42(4):747-56. PubMed ID: 11697505
[TBL] [Abstract][Full Text] [Related]
7. [Detection of aml-1/eto fusion gene in patients with acute myeloid leukemia by real-time quantitative RT-PCR].
Jiang YM; Yuan H; Liu XY; Wang B; Li SJ; Wang N
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):17-22. PubMed ID: 19236739
[TBL] [Abstract][Full Text] [Related]
8. Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia.
Müller MC; Hördt T; Paschka P; Merx K; La Rosée P; Hehlmann R; Hochhaus A
Acta Haematol; 2004; 112(1-2):30-3. PubMed ID: 15179002
[TBL] [Abstract][Full Text] [Related]
9. Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.
Ross DM; Watkins DB; Hughes TP; Branford S
Clin Chem; 2008 Sep; 54(9):1568-71. PubMed ID: 18641042
[TBL] [Abstract][Full Text] [Related]
10. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1).
Tamaki H; Mishima M; Kawakami M; Tsuboi A; Kim EH; Hosen N; Ikegame K; Murakami M; Fujioka T; Masuda T; Taniguchi Y; Nishida S; Osumi K; Soma T; Oji Y; Oka Y; Kawase I; Sugiyama H; Ogawa H
Int J Hematol; 2003 Nov; 78(4):349-56. PubMed ID: 14686494
[TBL] [Abstract][Full Text] [Related]
11. [Detection of common fusion transcript levels in untreated leukemia patients by real-time quantitative RT-PCR technique].
Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Le H; Ruan GR; Liu YR; Huang XJ; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2007 Jul; 28(7):433-7. PubMed ID: 18072623
[TBL] [Abstract][Full Text] [Related]
12. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.
Zhang L; Cao Z; Ruan M; Zeng Q; Zhao L; Li Q; Zou Y; Wang J; Zhu X
Pediatr Blood Cancer; 2014 Oct; 61(10):1761-6. PubMed ID: 24920269
[TBL] [Abstract][Full Text] [Related]
13. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
[TBL] [Abstract][Full Text] [Related]
14. [Standardization of quantitative detection of BCR-ABL gene expression by RQ-PCR in patients with chronic myeloid leukemia in cooperation with European Leukemia Net].
Sacha T; Zawada M; Czekalska S; Florek I; Mueller M; Gniot M; Jaźwiec B; Kyrcz-Krzemień S; Leszczyńska A; Lewandowski K; Matiakowska K; Solarska I; Stokłosa T; Skotnicki AB
Przegl Lek; 2010; 67(7):454-9. PubMed ID: 21387754
[TBL] [Abstract][Full Text] [Related]
15. Real-time quantitative reverse transcriptase polymerase chain reaction.
Fan H; Robetorye RS
Methods Mol Biol; 2010; 630():199-213. PubMed ID: 20300999
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
[TBL] [Abstract][Full Text] [Related]
17. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay.
Goh HG; Lin M; Fukushima T; Saglio G; Kim D; Choi SY; Kim SH; Lee J; Lee YS; Oh SM; Kim DW
Leuk Lymphoma; 2011 May; 52(5):896-904. PubMed ID: 21338281
[TBL] [Abstract][Full Text] [Related]
18. [Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients].
Qin YZ; Ruan GR; Li JL; Fu JY; Chang Y; Wang H; Li LD; Liu YR; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):649-52. PubMed ID: 16620548
[TBL] [Abstract][Full Text] [Related]
19. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
[TBL] [Abstract][Full Text] [Related]
20. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
